Mattia Loppini1,2, Alessandro Pisano3, Marco Di Maio3, Francesco La Camera4,5, Maddalena Casana4, Guido Grappiolo4,5. 1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy. mattia.loppini@hunimed.eu. 2. IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy. mattia.loppini@hunimed.eu. 3. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy. 4. IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy. 5. Fondazione Livio Sciutto Onlus, Università Degli Studi Di Genova, Campus Savona, Via Magliotto 2, 17100, Savona, Italy.
Abstract
PURPOSE: The pre-operative differential diagnosis between periprosthetic joint infections (PJIs) and aseptic failure is challenging particularly in low virulence and biofilm-related infections. This study aimed to assess the incidence and survival of patients with unexpected PJIs in a presumed aseptic revision of total hip (THA) and knee (TKA) arthroplasties. METHODS: A retrospective analysis of a prospective cohort of patients was performed with 295 patients undergoing THA (n = 241) or TKA (n = 54) revision for presumed aseptic causes. Patients were diagnosed with unexpected PJI taking into account leukocyte count in the synovial fluid, sonicate, synovial culture, and tissue cultures of samples collected during surgery. The primary endpoint was the infection-free implant survival rate at theone year follow-up. RESULTS: The unexpected PJIs were 60 out of 295 (20.3%), whereas 235 (79.7%) were aseptic revisions. In the unexpected PJI group, 6 (11.1%) patients underwent knee revision and 54 (22.4%) hip revision. At the one year follow-up, one patient (1.6%) in the unexpected PJI group and 3 (1.3%) in the aseptic group (p = 1.0) failed for infection. The infection-free implant survival rate at the one year follow-up was 98.3% (C.I. 95%, 94.9-99.9%) for the unexpected PJI group and 98.7% (C.I. 95%, 97.3-99.9%) (p = 0.82) for the aseptic group. CONCLUSION: The incidence of unexpected PJIs in a presumed aseptic revision of THAs and TKAs has been previously underestimated. The infection-free implant survival rate at the one year follow-up in patients with unexpected PJIs was not significantly lower compared with patients undergoing aseptic revision.
PURPOSE: The pre-operative differential diagnosis between periprosthetic joint infections (PJIs) and aseptic failure is challenging particularly in low virulence and biofilm-related infections. This study aimed to assess the incidence and survival of patients with unexpected PJIs in a presumed aseptic revision of total hip (THA) and knee (TKA) arthroplasties. METHODS: A retrospective analysis of a prospective cohort of patients was performed with 295 patients undergoing THA (n = 241) or TKA (n = 54) revision for presumed aseptic causes. Patients were diagnosed with unexpected PJI taking into account leukocyte count in the synovial fluid, sonicate, synovial culture, and tissue cultures of samples collected during surgery. The primary endpoint was the infection-free implant survival rate at theone year follow-up. RESULTS: The unexpected PJIs were 60 out of 295 (20.3%), whereas 235 (79.7%) were aseptic revisions. In the unexpected PJI group, 6 (11.1%) patients underwent knee revision and 54 (22.4%) hip revision. At the one year follow-up, one patient (1.6%) in the unexpected PJI group and 3 (1.3%) in the aseptic group (p = 1.0) failed for infection. The infection-free implant survival rate at the one year follow-up was 98.3% (C.I. 95%, 94.9-99.9%) for the unexpected PJI group and 98.7% (C.I. 95%, 97.3-99.9%) (p = 0.82) for the aseptic group. CONCLUSION: The incidence of unexpected PJIs in a presumed aseptic revision of THAs and TKAs has been previously underestimated. The infection-free implant survival rate at the one year follow-up in patients with unexpected PJIs was not significantly lower compared with patients undergoing aseptic revision.
Authors: Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Thomas P Vail; Daniel J Berry Journal: J Bone Joint Surg Am Date: 2009-01 Impact factor: 5.284
Authors: Benjamin Zmistowski; Craig Della Valle; Thomas W Bauer; Konstantinos N Malizos; Abbas Alavi; Hani Bedair; Robert E Booth; Peter Choong; Carl Deirmengian; Garth D Ehrlich; Anil Gambir; Ronald Huang; Yair Kissin; Hideo Kobayashi; Naomi Kobayashi; Veit Krenn; Lorenzo Drago; Drago Lorenzo; S B Marston; Geert Meermans; Javier Perez; J J Ploegmakers; Aaron Rosenberg; C Simpendorfer; Peter Thomas; Stephan Tohtz; Jorge A Villafuerte; Peter Wahl; Frank-Christiaan Wagenaar; Eivind Witzo Journal: J Arthroplasty Date: 2013-12-15 Impact factor: 4.757
Authors: A Ribera; L Morata; J Moranas; J L Agulló; J C Martínez; Y López; D García; J Cabo; S García-Ramiro; A Soriano; O Murillo Journal: J Infect Date: 2014-05-23 Impact factor: 6.072
Authors: Dirk Jan F Moojen; Gijs van Hellemondt; H Charles Vogely; Bart J Burger; Geert H I M Walenkamp; Niek J A Tulp; B Wim Schreurs; Frank R A J de Meulemeester; Corrie S Schot; Ingrid van de Pol; Takaaki Fujishiro; Leo M Schouls; Thomas W Bauer; Wouter J A Dhert Journal: Acta Orthop Date: 2010-10-04 Impact factor: 3.717
Authors: Marta Fernandez-Sampedro; Carlos Salas-Venero; Concepción Fariñas-Álvarez; Manuel Sumillera; Luis Pérez-Carro; Michel Fakkas-Fernandez; Javier Gómez-Román; Luis Martínez-Martínez; María Carmen Fariñas Journal: BMC Infect Dis Date: 2015-06-18 Impact factor: 3.090
Authors: Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Vanessa Chiu; Thomas P Vail; Harry E Rubash; Daniel J Berry Journal: Clin Orthop Relat Res Date: 2009-06-25 Impact factor: 4.176